FDA Approves Apalutamide for Nonmetastatic Prostate Cancer!

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Click Here to Read the Full Press Announcement.

 

What I know now I wish I knew before…getting checked early can save your life.

~John Sharp, prostate cancer survivor

Join Our Newsletter